Serotonin transporter binding of [123I]ADAM in bulimic women, their healthy twin sisters, and healthy women: A SPET study

BMC Psychiatry

Volumn 7, Issue , 2007, Pages

  Koskela, Anu K ^a   Keski Rahkonen, Anna ^b   Sihvola, Elina ^b   Kauppinen, Tomi ^a   Kaprio, Jaakko ^b,c   Ahonen, Aapo ^a   Rissanen, Aila ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; IODINE 123; SEROTONIN TRANSPORTER; 2 ((2 ((DIMETHYLAMINO)METHYL)PHENYL)THIO) 5 IODOPHENYLAMINE; 2-((2-((DIMETHYLAMINO)METHYL)PHENYL)THIO)-5-IODOPHENYLAMINE; CINANSERIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; SEROTONIN; SLC6A4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; BULIMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; HEREDITY; HUMAN; MESENCEPHALON; PHENOTYPE; POST HOC ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; GENETICS; LONGITUDINAL STUDY; METABOLISM; PHYSIOLOGY; TWINS;

ADULT; BULIMIA; CINANSERIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; PHENOTYPE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 34250683806     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-7-19     Document Type: Article

References (55)

1. American Psychiatric Association DSM IV: Diagnostic and statistical manual of mental disorders Washington, DC, American Psychiatric Association 4 1994
2. Kaltiala-Heino R Rissanen A Rimpela M Rantanen P Bulimia and impulsive behaviour in middle adolescence Psychother Psychosom 2003 72 26-33 10.1159/000067187 12466635
3. Leibowitz SF Alexander JT Hypothalamic serotonin in control of eating behavior, meal size, and body weight Biol Psychiatry 1998 44 851-864 10.1016/S0006-3223(98)00186-3 9807640
4. Goldbloom DS Hicks LK Garfinkel PE Platelet serotonin uptake in bulimia nervosa Biol Psychiatry 1990 28 644-647 10.1016/0006-3223(90)90404-P 2223931
5. Goldbloom DS Garfinkel PE Katz R Brown GM The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa J Psychosom Res 1996 40 289-297 10.1016/0022-3999(95)00640-0 8861125
6. Jimerson DC Lesem MD Kaye WH Brewerton TD Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes Arch Gen Psychiatry 1992 49 132-138 1372494
7. Jimerson DC Wolfe BE Metzger ED Finkelstein DM Cooper TB Levine JM Decreased serotonin function in bulimia nervosa Arch Gen Psychiatry 1997 54 529-534 9193193
8. Kaye WH Ballenger JC Lydiard RB Stuart GW Laraia MT O'Neil P Fossey MD Stevens V Lesser S Hsu G CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity Am J Psychiatry 1990 147 225-229 1689122
9. Kaye W Gendall K Strober M Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa Biol Psychiatry 1998 44 825-838 10.1016/S0006-3223(98)00195-4 9807638
10. Kaye WH Gendall KA Fernstrom MH Fernstrom JD McConaha CW Weltzin TE Effects of acute tryptophan depletion on mood in bulimia nervosa Biol Psychiatry 2000 47 151-157 10.1016/S0006-3223(99)00108-0 10664832
11. Smith KA Fairburn CG Cowen PJ Symptomatic relapse in bulimia nervosa following acute tryptophan depletion Arch Gen Psychiatry 1999 56 171-176 10.1001/archpsyc.56.2.171 10025442
12. Mitchell JE Raymond N Specker S A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa Int J Eat Disord 1993 14 229-247 10.1002/ 1098-108X(199311)14:3<229::AID-EAT2260140302>3.0.CO;2-X 8275060
13. Walsh BT Psychopharmacologic treatment of bulimia nervosa J Clin Psychiatry 1991 52 Suppl 34-38 1938987
14. Kaye WH Bulik CM Thornton L Barbarich N Masters K Comorbidity of anxiety disorders with anorexia and bulimia nervosa Am J Psychiatry 2004 161 2215-2221 10.1176/appi.ajp.161.12.2215 15569892
15. Kaye WH Greeno CG Moss H Fernstrom J Fernstrom M Lilenfeld LR Weltzin TE Mann JJ Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa Arch Gen Psychiatry 1998 55 927-935 10.1001/archpsyc.55.10.927 9783564
16. Kaye WH Frank GK Meltzer CC Price JC McConaha CW Crossan PJ Klump KL Rhodes L Altered serotonin 2A receptor activity in women who have recovered from bulimia nervosa Am J Psychiatry 2001 158 1152-1155 10.1176/appi.ajp.158.7.1152 11431241
17. Bulik CM Sullivan PF Wade TD Kendler KS Twin studies of eating disorders: A review Int J Eat Disord 2000 27 1-20 10.1002/ (SICI)1098-108X(200001)27:1<1::AID-EAT1>3.0.CO;2-Q 10590444
18. Tauscher J Pirker W Willeit M de Zwaan M Bailer U Neumeister A Asenbaum S Lennkh C Praschak-Rieder N Brucke T Kasper S [123] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa Biol Psychiatry 2001 49 326-332 10.1016/S0006-3223(00)00951-3 11239903
19. Kuikka JT Tammela L Karhunen L Rissanen A Bergstrom KA Naukkarinen H Vanninen E Karhu J Lappalainen R Repo-Tiihonen E Tiihonen J Uusitupa M Reduced serotonin transporter binding in binge eating women Psychopharmacology 2001 155 310-314 10.1007/s002130100716 11432694
20. Tiihonen J Keski-Rahkonen A Lopponen M Muhonen M Kajander J Allonen T Nagren K Hietala J Rissanen A Brain serotonin 1A receptor binding in bulimia nervosa Biol Psychiatry 2004 55 871-873 10.1016/ j.biopsych.2003.12.016 15050870
21. Bailer UF Price JC Meltzer CC Mathis CA Frank GK Weissfeld L McConaha CW Henry SE Brooks-Achenbach S Barbarich NC Kaye WH Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness Neuropsychopharmacology 2004 29 1143-1155 10.1038/sj.npp.1300430 15054474
22. Oya S Choi SR Hou C Mu M Kung MP Acton PD Siciliano M Kung HF 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An improved serotonin transporter ligand Nucl Med Biol 2000 27 249-254 10.1016/S0969-8051(00)00084-6 10832081
23. Catafau AM Perez V Penengo MM Bullich S Danus M Puigdemont D Corripio I Pascual C Perich X Alvarez E SPECT of serotonin transporters using 123I-ADAM: Optimal imaging time after bolus injection and long-term test-retest in healthy volunteers J Nucl Med 2005 46 1301-1309 16085586
24. Erlandsson K Sivananthan T Lui D Spezzi A Townsend CE Mu S Lucas R Warrington S Ell PJ Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: A SPECT validation study Eur J Nucl Med Mol Imaging 2005 32 1329-1336 10.1007/s00259-005-1912-y 16133377
25. Kauppinen TA Bergström KA Heikman P Hiltunen J Ahonen AK Biodistribution and radiation dosimetry of (123-I)-ADAM in healthy human subjects: Preliminary results Eur J Nucl Med Mol Imaging 2003 30 132-136 10.1007/s00259-002-1027-7 12483421
26. Newberg AB Plossl K Mozley PD Stubbs JB Wintering N Udeshi M Alavi A Kauppinen T Kung HF Biodistribution and imaging with (123)I-ADAM: A serotonin transporter imaging agent J Nucl Med 2004 45 834-841 15136634
27. 123I]ADAM Nuklearmedizin 2005 44 205 212 16395497
28. Kaprio J Pulkkinen L Rose RJ Genetic and environmental factors in health-related behaviors: Studies on Finnish twins and twin families Twin Res 2002 5 366-371 10.1375/136905202320906101 12537860
29. First MB Spitzer RL Gibbon M Williams JBW Structured Clinical Interview for DSM-IV Axis I and Axis II Disorders New York.: Biometrics Research Department, New York State Psychiatric Institute 1997
30. Keski-Rahkonen A Sihvola E Raevuori A Kaukoranta J Bulik CM Hoek HW Rissanen A Kaprio J Reliability of self-reported eating disorders: Optimizing population screening Int J Eat Disord 2006 39 754-62 10.1002/ eat.20277 16937380
31. Anderluh MB Tchanturia K Rabe-Hesketh S Treasure J Childhood obsessive-compulsive personality traits in adult women with eating disorders: Defining a broader eating disorder phenotype Am J Psychiatry 2003 160 242-247 10.1176/appi.ajp.160.2.242 12562569
32. Bucholz KK Cadoret R Cloninger CR Dinwiddie SH Hesselbrock VM Nurnberger JI Jr Reich T Schmidt I Schuckit MA A new, semi-structured psychiatric interview for use in genetic linkage studies: A report on the reliability of the SSAGA J Stud Alcohol 1994 55 149-158 8189735
33. Wade T Heath AC Abraham S Treloar SA Martin NG Tiggemann M Assessing the prevalence of eating disorders in an Australian twin population Aust N Z J Psychiatry 1996 30 845-851 9034476
34. Backstrom I Bergstrom M Marcusson J High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue Brain Res 1989 486 261-268 10.1016/0006-8993(89)90511-8 2525060
35. Frokjaer VG Pinborg LH Madsen J deNijs R Knudsen GM Evaluation of the Serotonin Transporter Ligand [I-123]ADAM for SPECT Studies in Humans [abstract] Annales Universitatis Turkuensis D 660: Turku PET symposium 2005 Turku, Turun Yliopisto Nyman MJ, Oikonen V, Turiceanu M, Scheinen H 2005 78
36. Kaye WH Frank GK Bailer UF Henry SE Meltzer CC Price JC Mathis CA Wagner A Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies Physiol Behav 2005 85 73-81 10.1016/ j.physbeh.2005.04.013 15869768
37. Uher R Murphy T Friederich HC Dalgleish T Brammer MJ Giampietro V Phillips ML Andrew CM Ng VW Williams SC Campbell IC Treasure J Functional neuroanatomy of body shape perception in healthy and eating-disordered women Biol Psychiatry 2005 58 990-997 10.1016/ j.biopsych.2005.06.001 16084858
38. Walsh BT Fluoxetine treatment of bulimia nervosa J Psychosom Res 1991 Suppl 1 33-40
39. Vaswani M Linda FK Ramesh S Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review Prog Neuropsychopharmacol Biol Psychiatry 2003 27 85-102 10.1016/ S0278-5846(02)00338-X 12551730
40. Fuller RW Pharmacologic modification of serotonergic function: Drugs for the study and treatment of psychiatric and other disorders J Clin Psychiatry 1986 47 Suppl 4-8 3514585
41. Gonzalez-Heydrich J Peroutka SJ Serotonin receptor and reuptake sites: pharmacologic significance J Clin Psychiatry 1990 51 Suppl 5-12 2157701
42. Goodwin GM How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs J Clin Psychiatry 1996 57 Suppl 4 9-13 8636065
43. Stahl SM Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects J Affect Disord 1998 51 215-235 10.1016/S0165-0327(98)00221-3 10333979
44. Petty F Davis LL Kabel D Kramer GL Serotonin dysfunction disorders: A behavioral neurochemistry perspective J Clin Psychiatry 1996 57 Suppl 8 11-16 8698675
45. Coyle JT Duman RS Finding the intracellular signaling pathways affected by mood disorder treatments Neuron 2003 38 157-160 10.1016/ S0896-6273(03)00195-8 12718851
46. Reba L Thornton L Tozzi F Klump KL Brandt H Crawford S Crow S Fichter MM Halmi KA Johnson C Kaplan AS Keel P LaVia M Mitchell J Strober M Woodside DB Rotondo A Berrettini WH Kaye WH Bulik CM Relationships between features associated with vomiting in purging-type eating disorders Int J Eat Disord 2005 38 287-294 10.1002/eat.20189 16261604
47. Innis R Baldwin R Sybirska E Zea Y Laruelle M al-Tikriti M Charney D Zoghbi S Smith E Wisniewski G Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT Eur J Pharmacol 1991 200 369-370 10.1016/0014-2999(91)90599-L 1782997
48. Laruelle M Baldwin RM Malison RT Zea-Ponce Y Zoghbi SS al-Tikriti MS Sybirska EH Zimmermann RC Wisniewski G Neumeyer JL SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: Pharmacological characterization of brain uptake in nonhuman primates Synapse 1993 13 295-309 10.1002/syn.890130402 7683143
49. Neumeyer JL Tamagnan G Wang S Gao Y Milius RA Kula NS Baldessarini RJ N-substituted analogs of 2 beta-carbomethoxy-3 beta-(4′-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain J Med Chem 1996 39 543-548 10.1021/jm9505324 8558525
50. Ramamoorthy S Blakely RD Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants Science 1999 285 763-766 10.1126/science.285.5428.763 10427004
51. Milak MS Ogden RT Vinocur DN Van Heertum RL Cooper TB Mann JJ Parsey RV Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: Response to acute serotonin deficiency Biol Psychiatry 2005 57 102-106 10.1016/j.biopsych.2004.09.026 15607307
52. Talbot PS Frankle WG Hwang DR Huang Y Suckow RF Slifstein M Abi-Dargham A Laruelle M Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans Synapse 2005 55 164-175 10.1002/syn.20105 15605360
53. Lundquist P Roman M Syvanen S Hartvig P Blomquist G Hammarlund-Udenaes M Langstrom B Effect on [(11)C]DASB binding after tranylcypromine-induced increase in serotonin concentration: Positron emission tomography studies in monkeys and rats Synapse 2007 61 440-449 10.1002/syn.20382 17372973
54. Wihlback AC Sundstrom Poromaa I Bixo M Allard P Mjorndal T Spigset O Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding Psychoneuroendocrinology 2004 29 757-766 10.1016/S0306-4530(03)00120-3 15110925
55. Best SE Sarrel PM Malison RT Laruelle M Zoghbi SS Baldwin RM Seibyl JP Innis RB van Dyck CH Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle Psychopharmacology 2005 183 181-189 10.1007/s00213-005-0158-5 16175405